<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="5624">
  <stage>Registered</stage>
  <submitdate>24/05/2012</submitdate>
  <approvaldate>24/05/2012</approvaldate>
  <nctid>NCT01609140</nctid>
  <trial_identification>
    <studytitle>A Phase II Study of the Safety and Efficacy of MPSK3169A in Patients With Coronary Heart Disease or High Risk of Coronary Heart Disease</studytitle>
    <scientifictitle>A Phase II, Randomized, Placebo-Controlled, Double-Blind Study of the Safety and Efficacy of MPSK3169A in Patients With Coronary Heart Disease or High Risk of Coronary Heart Disease</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>GC28210</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Coronary Heart Disease</healthcondition>
    <conditioncode>
      <conditioncode1>Cardiovascular </conditioncode1>
      <conditioncode2>Coronary heart disease</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Cardiovascular </conditioncode1>
      <conditioncode2>Other cardiovascular diseases</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - MPSK3169A
Treatment: drugs - MPSK3169A
Treatment: drugs - MPSK3169A
Treatment: drugs - MPSK3169A
Treatment: drugs - MPSK3169A
Treatment: drugs - Placebo

Experimental: A - 

Experimental: B - 

Experimental: C - 

Experimental: D - 

Experimental: E - 

Placebo Comparator: F - 


Treatment: drugs: MPSK3169A
Dose regimen A, repeating subcutaneous injections every 4 weeks

Treatment: drugs: MPSK3169A
Dose regimen E, repeating subcutaneous injections every 4 weeks

Treatment: drugs: MPSK3169A
Dose regimen D, repeating subcutaneous injections every 4 weeks

Treatment: drugs: MPSK3169A
Dose regimen C, repeating subcutaneous injections every 4 weeks

Treatment: drugs: MPSK3169A
Dose regimen B, repeating subcutaneous injections every 4 weeks

Treatment: drugs: Placebo
Repeating subcutaneous injections of placebo every 4 weeks

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Absolute change from baseline in LDL-c concentration</outcome>
      <timepoint>at Day 169</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Absolute change from baseline in LDL-c concentration for each arm at the nadir for that arm</outcome>
      <timepoint>over the 24 week treatment period</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Average value over time of the change in LDL-c (absolute and percent change) for each arm, up to Day 169, weighted by the number of weeks between consecutive LDL-c measurements</outcome>
      <timepoint>up to Day 169</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Percent change from baseline in LDL-c concentration at Day 169 and at the nadir for each arm</outcome>
      <timepoint>at Day 169 and over the 24 week treatment period</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Percent and absolute change from baseline in LDL-c concentration at all other designated timepoints</outcome>
      <timepoint>at all other designated timepoints</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Percent and absolute change from baseline in total cholesterol, non-HDL-c, and apolipoprotein B (ApoB) at Day 169 and at the nadir for each arm</outcome>
      <timepoint>at Day 169 and over the 24 week treatment period</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  Use of a standard-of-care statin at a stable dose, or intolerance of statins, without
             use of other lipid modifying therapies

          -  Fasting LDL cholesterol 90-250 mg/dL on the statin regimen above

        And at least one of the following:

          -  Coronary heart disease (CHD) with a history of myocardial infarction (MI),
             percutaneous coronary intervention (PCI), coronary artery bypass graft surgery (CABG),
             or prior coronary angiography demonstrating coronary atherosclerosis

          -  A CHD risk equivalent condition, including diabetes mellitus (type 1 or 2), chronic
             kidney disease, prior stroke, carotid disease, peripheral arterial disease, or
             abdominal aortic aneurism

          -  &gt;/=2 CHD risk factors (age &gt;/= 45 years for men or &gt;/= 55 years for women; smoking;
             hypertension; low HDL cholesterol; family history of premature CHD) and a high risk of
             a CV event based on risk estimation systems</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>80</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  Severe congestive heart failure (NYHA Class III-IV) or left ventricular ejection
             fraction &lt;/= 35%

          -  Recent (within 3 months) MI, unstable angina, stroke, transient ischemic attack, CABG,
             PCI, hospital admission for heart failure, major surgery, uncontrolled cardiac
             arrhythmia (other than atrial fibrillation or flutter), or initiation of renal
             replacement therapy (dialysis)

          -  Fasting serum triglyceride level &gt;/= 400 mg/dL

          -  Homozygous familial hypercholesterolemia

          -  Poorly controlled diabetes mellitus, hypertension or thyroid disease

          -  Liver or muscle disease, including abnormal test results at screening

          -  Pregnant or lactating

        The above list is not intended to contain all factors relevant to a patient's eligibility
        for the study.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1>The people receiving the treatment/s</masking1>
    <masking2 />
    <masking3 />
    <masking4>The people analysing the results/data</masking4>
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 2</phase>
    <anticipatedstartdate />
    <actualstartdate>1/05/2012</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>248</actualsamplesize>
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>1/07/2013</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry />
    <recruitmentstate />
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Arizona</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>California</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Florida</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Idaho</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Indiana</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Iowa</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Maine</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Maryland</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Missouri</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>New York</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>North Carolina</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>North Dakota</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Ohio</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Oklahoma</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>South Carolina</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>South Dakota</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Tennessee</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Texas</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Virginia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Washington</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Newfoundland and Labrador</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Ontario</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Quebec</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Czech Republic</country>
      <state>Hodonin</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Czech Republic</country>
      <state>Jicícin</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Czech Republic</country>
      <state>Marianske Lazne</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Czech Republic</country>
      <state>Ostrava - Poruba</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Czech Republic</country>
      <state>Rakovník</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Berlin</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Köln</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Hungary</country>
      <state>Komarom</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Hungary</country>
      <state>Nagykanizsa</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Hungary</country>
      <state>Nyíregyháza</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Hungary</country>
      <state>Sopron</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>New Zealand</country>
      <state>Auckland</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>New Zealand</country>
      <state>Christchurch</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>New Zealand</country>
      <state>Nelson</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>New Zealand</country>
      <state>Tauranga</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Norway</country>
      <state>Elverum</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Norway</country>
      <state>Hamar</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Norway</country>
      <state>Oslo</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Norway</country>
      <state>Sandnes</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Slovakia</country>
      <state>Bardejov</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Slovakia</country>
      <state>Bratislava</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Slovakia</country>
      <state>Presov</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Slovakia</country>
      <state>Rimavska Sobota</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>South Africa</country>
      <state>Cape Town</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>South Africa</country>
      <state>Centurion</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>South Africa</country>
      <state>Pretoria</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Genentech, Inc.</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>The purpose of this study is to evaluate the safety and cholesterol lowering effects of
      MPSK3169A when given as subcutaneous (SC) injections over a 24-week period to patients with a
      high risk of cardiovascular events and LDL-c levels well above goal.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT01609140</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Clinical Trials</name>
      <address>Genentech, Inc.</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>